Active Ingredient History
Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors. Common adverse reactions include headache, abdominal pain, back pain, vomiting, dyspepsia, diarrhea, dizziness. Riluzole-treated patients that take other hepatotoxic drugs may be at increased risk for hepatotoxicity. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Amyotrophic Lateral Sclerosis (approved 1995)
Affect (Phase 4)
Alzheimer Disease (Phase 2/Phase 3)
Amyotrophic Lateral Sclerosis (Phase 4)
Anxiety Disorders (Phase 3)
Asperger Syndrome (Phase 2)
Autism Spectrum Disorder (Phase 2/Phase 3)
Autistic Disorder (Phase 2)
Bipolar Disorder (Phase 2)
Breast Neoplasms (Phase 1)
Cerebellar Ataxia (Phase 2/Phase 3)
Cervix Uteri (Phase 3)
Cocaine-Related Disorders (Phase 1)
Colorectal Neoplasms (Phase 1)
Depression (Phase 4)
Depressive Disorder, Major (Phase 2)
Erectile Dysfunction (Phase 3)
Fatigue (Phase 4)
Fragile X Syndrome (Phase 4)
Growth and Development (Phase 2)
Healthy Volunteers (Phase 1)
Huntington Disease (Phase 3)
Inflammation (Phase 4)
Machado-Joseph Disease (Phase 3)
Melanoma (Phase 2)
Memory Disorders (Phase 4)
Mood Disorders (Phase 1/Phase 2)
Multiple Sclerosis (Phase 2)
Multiple Sclerosis, Chronic Progressive (Phase 2)
Multiple System Atrophy (Phase 3)
Muscular Atrophy, Spinal (Phase 2/Phase 3)
Neoplasms (Phase 1)
Nerve Degeneration (Phase 2)
Neuromuscular Diseases (Phase 1/Phase 2)
Obsessive Behavior (Phase 2)
Obsessive-Compulsive Disorder (Phase 3)
Prostatitis (Phase 3)
Sexual Health (Phase 3)
Spinal Cord Compression (Phase 3)
Spinal Cord Injuries (Phase 2/Phase 3)
Spinocerebellar Ataxias (Phase 3)
Spinocerebellar Degenerations (Phase 2)
Stress Disorders, Post-Traumatic (Phase 1/Phase 2)
Supranuclear Palsy, Progressive (Phase 3)
Therapeutic Equivalency (Phase 1)
Tourette Syndrome (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
